Showing 1421-1430 of 1537 results for "".
- BioFactura Starts Phase I Study of BFI-751, a Stelara Biosimilarhttps://practicaldermatology.com/news/biofactura-starts-phase-i-study-of-bfi-751-a-stelara-biosimilar/2460811/BioFactura is set to begin a pivotal pharmacokinetics Phase 1 clinical trial for its Ustekinumab biosimilar BFI-751. The first-in-human Phase I study will assess the effects on healthy human volunteers compared to the biologic medicine, Stelara. This is the first time BFI-751 has been a
- Phase I Trial for Implantable Melanoma Vaccine Beginshttps://practicaldermatology.com/news/20130910-phase_i_trial_for_implantable_melanoma_vaccine_begins/2459466/
- Biosimilar Update: Dr. Reddy’s Completes Phase I Study of Proposed Tocilizumab Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-dr-reddys-completes-phase-i-study-of-proposed-tocilizumab-biosimilar/2461765/Dr. Reddy’s Laboratories’ tocilizumab biosimilar candidate, DRL_TC, met its primary and secondary endpoints in a Phase I study. The company is now initiating a global Phase III study with the aim of comparing the efficacy, safety, tolerability and immunogeni
- Kintor Pharma Completes Enrollment and Dosing in Phase I Clinical Trial of AGA, Acne Drughttps://practicaldermatology.com/news/kintor-pharma-completes-enrollment-and-dosing-in-phase-i-clinical-trial-of-aga-acne-drug/2461404/Kintor Pharmaceutical Limited has completed the enrollment and dosing of 120 subjects for its U.S. phase I clinical trial of GT20029 for the treatment of androgenetic alopecia (AGA) and acne. Developed through Kintor Pharma's proprietary Proteolysis Targeting Chimera (PROTAC) platfo
- Kintor Doses First Group of Acne Patients in Phase I/II Clinical Trial of Pyrilutamidehttps://practicaldermatology.com/news/kintor-doses-first-group-of-acne-patients-in-phase-iii-clinical-trial-of-pyrilutamide/2460752/Kintor Pharmaceutical Limited successfully dosed the first group of patients in the clinical trial of Pyrilutamide as a treatment for the acne vulgaris. The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evalu
- Lead Pharma Begins Phase I Trials with SAR441169 Candidate Treatment for Psoriasishttps://practicaldermatology.com/news/lead-pharma-to-begin-phase-i-trials-with-sar441169-candidate-treatment-for-psoriasis/2459962/Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of immunological and oncological indications, achieved a fourth milestone under its license & collaboration agreement with Sanofi, triggering an undisclosed milestone payment. The milestone payment is link
- Phase I Trial of Nivolumab Shows Long-Term Efficacy Against Melanomahttps://practicaldermatology.com/news/20140313-phase_i_trial_of_nivolumab_shows_long-term_efficacy_against_melanoma/2459318/A recent study by researchers at Dana-Farber Cancer Institute, Johns Hopkins University, Yale University, and allied institutions, published online in the Journal of Clinical Oncology, provides the longest-term look so far at how melanom
- About 415 Million People May Have Rosacea Worldwidehttps://practicaldermatology.com/news/about-415-million-people-may-have-rosacea-worldwide/2457701/As many as 415 million people worldwide may have rosacea, according to new research in the British Journal of Dermatology. Dr. Jacob Thyssen and colleagues at the University of Copenhagen, Denmark, conducted
- Harvard Business Review Names Allergan's David E. I. Pyott a Top CEOhttps://practicaldermatology.com/news/20141015-harvard_business_review_names_allergans_david_e_i_pyott_a_top_ceo/2459084/David E.I. Pyott, Chairman of the Board and Chief Executive Officer of Allergan, Inc., has been ranked the 4th best-performing CEO in the world by the Harvard Business Review (HBR). Mr. Pyott was selected for this honor out of a total o
- Congress Establishes New Caucus on Skin Cancerhttps://practicaldermatology.com/news/20130708-congress_establishes_new_caucus_on_skin_cancer/2459502/A new bipartisan Congressional Member Organization will address the growing epidemic of skin cancer among Americans. Led by representatives Jim Cooper (D-TN-5th), Carolyn Maloney (D-NY-12th), Peter Roskam (R-IL-6th), and Charlie Dent (R-PA-15th), the caucus will support legislative activities and pr